"2022 was another momentous year for Keros – consistent execution throughout last year has positioned Keros to deliver on several key upcoming milestones in 2023," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. "We are excited by the momentum and engagement around our two ongoing Phase 2 clinical trials of KER-050, one in patients with myelodysplastic syndromes ("MDS") and one in patients with myelofibrosis, as we believe KER-050 has significant potential to address unmet patient need in a differentiated way. Additionally, we will continue to leverage our understanding of the transforming growth factor-beta family of proteins to research our library of proprietary molecules, in order to expand our development programs related to hematological, pulmonary and cardiovascular disorders."
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KROS:
- Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
- Keros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
- Keros Therapeutics initiated with an Outperform at Cowen
- Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue